ArticleScientific reports2018
E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.
Wenjun Lan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this papercites it